| Title: | Association of Genetic Predisposition to Inflammation With Cancer-Related Cognitive Impairment and Fatigue in Women Who Received Chemotherapy for Nonmetastatic Breast Cancer |
| Journal: | JCO Precision Oncology |
| Published: | 16 Sep 2025 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/40956996/ |
| DOI: | https://doi.org/10.1200/po-25-00303 |
Publication 19492
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
PURPOSE: Cancer-related cognitive impairment (CRCI) and cancer-related fatigue (CRF) are reported by approximately 75% of patients receiving chemotherapy for breast cancer and both have been linked to inflammation. We sought to test whether an inflammation polygenic risk score (iPRS) might be associated with CRCI and/or CRF.</p>
METHODS: Using data from the UK Biobank, we developed an iPRS for the INFLA-Score, a composite measure of C-reactive protein, white cell count, platelet count, and neutrophil-lymphocyte ratio. The iPRS was evaluated for association with CRCI and CRF among women with nonmetastatic breast cancer enrolled in two completed multisite clinical trials: URCC08106 and URCC10055. CRCI and CRF were measured before and after standard-of-care chemotherapy using the FACT-Cog and Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), respectively. Linear regression evaluated the change in FACT-Cog and MFSI scores; logistic regression evaluated binary outcomes of any versus no worsening of scores. Analyses were adjusted for patient and treatment factors. We also performed exploratory genome-wide analyses.</p>
RESULTS: The cohort included 802 women who received chemotherapy (anthracycline-based = 51.8%; previous surgery = 85.0%) at a median age of 55 years (range = 22-81). The iPRS was associated with a significant decrease in MFSI-SF score (β = -3.29 [95% CI, -6.25 to -0.34]; P = .029) and lower odds of decreased MFSI-SF score (odds ratio, 0.66 [95% CI, 0.47 to 0.93]; P = .016) following chemotherapy. This negative relationship was partially explained by a positive correlation of the iPRS with prechemotherapy MFSI-SF score (β = 4.33 [95% CI, 0.23 to 8.43]; P = .038). The iPRS was not associated with a change in FACT-Cog score (β = -1.12; P = .627), but single nucleotide polymorphism rs9365961 was (β = -10.05; P = 1.46 × 10-8).</p>
CONCLUSION: If validated, the iPRS could identify patients in need of supportive care interventions to reduce CRF.</p>
10 Keywords
- Adult
- Aged
- Breast Neoplasms
- Chemotherapy-Related Cognitive Impairment
- Fatigue
- Female
- Genetic Predisposition to Disease
- Humans
- Inflammation
- Middle Aged
11 Authors
- Ayokunle S. Olowofela
- Paul L. Auer
- Michelle Janelsins
- Karen Mustian
- Alison Conlin
- Adedayo A. Onitilo
- Marianne Melnik
- Chin-Shang Li
- Umang Gada
- Hongying Sun
- Sarah L. Kerns
Enabling scientific discoveries that improve human health